SKYE Stock Analysis
SK
Uncovered
Skye Bioscience Inc is uncovered by Eyestock quantitative analysis.
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The firm is focused on the discovery, development and commercialization of a class of cannabinoid derivatives to modulate the endocannabinoid system. The firm is also focused on developing cannabinoid derivatives that have the potential to treat ophthalmic disorders and other diseases with unmet needs. Its lead product candidate, SBI-100, is being developed for the treatment of glaucoma and ocular hypertension. SBI-100 is designed to make the usually lipophilic cannabinoid more hydrophilic to allow for improved transport across the membranes of the eye. The company is also focused on developing different formulations of SBI-200. Early studies of SBI-200 demonstrated analgesic, anti- inflammatory, anti-fibrotic and anti-seizure properties, including the potential treatment and management of several eye diseases, such as uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.